Seattle Genetics Inc. (NASDAQ:SGEN) changes shares on Tuesday trading session, with a change of -2.35% or -$3.97 shares. The trading starts at $168.73 and closed at $169.04 throughout the day. The trading session low price was $162.8449 and day high was $168.73 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.7 million while its average volume is 1.28M. In other hand, the SGEN market cap reached to $29.41B. While, its current target price is $172.69.
On June 29, 2020, BRIEF-Seattle Genetics Announces Positive Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin. According to the news reported on Reuters, * SEATTLE GENETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.67% and down -3.16% for month. Its quarterly performance was -0.22% below, while its half year performance is up 48.03%. SGEN yearly performance stood at positive 126.25% and rise 44.47% for year-to-date. Current recommendation for Seattle Genetics Inc. is 2.20.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. SGEN EPS (TTM) for 12-month is -1.50. EPS for this year is 32.10%, while for the next year its value is -0.36. Its EPS Q/Q reached 75.10%. It has an EPS of -9.20% down for past five years.
Let’s take a look on the analyst recommendations on SGEN for the current month and previous month. For the current month, 11 of 19 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 1 as underweight and 7 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $145.00 – $253.00. Average target price for SGEN was reached at $182.94.
Baker Brothers Advisors, LLC, Capital International Investors and Vanguard Group, Inc. (The) are the top three holders in Seattle Genetics Inc. (SGEN) stock. On Mar 30, 2020, Baker Brothers Advisors, LLC has 50.06 million shares which valued 5.78 billion. On Mar 30, 2020, Capital International Investors owned 18.47 million shares which valued at 2.13 billion. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 11.31 million shares which valued at 1.3 billion. In the end, Vanguard Group, Inc. (The) have 6.53% shares outstanding of Seattle Genetics Inc. (SGEN) on Mar 30, 2020. The insider ownership moved to 1.00% and institutional holding shifted to 94.31%.
The company posted an EPS (TTM) of -1.50. According to the most recent quarter report on (Sep 2020), 16 analysts estimated an average EPS of -0.55, while -0.55 EPS posted a year ago period. Analyst Estimated EPS for SGEN published in the report was -$0.69 – -$0.41 during the same period. Comparing with last year, the average estimated EPS was -0.55 which is lower than -0.12 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for SGEN rise 26.76% for period of 200 days. SMA for 50 days was -0.16% which is showing red signal, while SMA-20 was -5.28%. The moving average value for Seattle Genetics Inc. (SGEN) is 4.61M and 2.31% for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in SGEN stock. On Jul 17, HIMES VAUGHN B, Chief Technical Officer, sold 8,000 trading shares at the cost of $179.42, which valued at 1.44 million. On Jul 08, SIEGALL CLAY B, President and CEO, sold 28,472 shares at the cost of $175.08, with total shares of 718,339. On Jul 02, ROMP CHARLES R, EVP, Commercial, sold 712 shares at the cost of 167.49. After this transaction, ROMP CHARLES R total shares reached to 55,307 which valued at 0.12 million.